|

July 26, 2016

BioTelemetry, Inc. Announces FDA Approval of Its Next Generation Device, the MCOT™ Patch

BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance of its next generation Mobile Cardiac Outpatient Telemetry™ device, the MCOT™ Patch.